Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements about Entresto’s pregnancy/fetal toxicity align with the provided label excerpts, including that ENTRESTO can cause fetal harm and should be discontinued when pregnancy is detected. However, multiple other claims are unsupported by the supplied prescribing information (only Sections 5.1 and 8.1 were provided), preventing full verification.
Category Scores
Accurate Statements
Entresto can cause fetal toxicity including injury and death to a developing fetus.
Supported by provided label excerpt(s): Section 5.1 states ENTRESTO can cause fetal harm; Section 8.1 describes increased fetal and neonatal morbidity and death and related fetal/neonatal adverse reactions (e.g., death).
When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO.
Supported by Section 5.1 and Section 8.1: 'When pregnancy is detected, consider alternative drug treatment and discontinue ENTRESTO.'
Unsupported Statements
Entresto is a medication prescribed for heart failure with reduced ejection fraction.
Not supported by the supplied label excerpts (only Sections 5.1 and 8.1 were provided).
Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction.
Not supported by the supplied label excerpts.
Entresto is a combination drug containing sacubitril and valsartan.
The label excerpts provided do not address composition; only pregnancy/fetal toxicity content was supplied.
Entresto combines sacubitril, a neprilysin inhibitor, with valsartan, an angiotensin II receptor blocker (ARB).
Not supported by the supplied label excerpts.
Sacubitril inhibits neprilysin.
Not supported by the supplied label excerpts.
Neprilysin breaks down natriuretic peptides.
Not supported by the supplied label excerpts.
Natriuretic peptides have beneficial cardiovascular effects such as vasodilation and natriuresis.
Not supported by the supplied label excerpts.
By inhibiting neprilysin, sacubitril increases levels of natriuretic peptides.
Not supported by the supplied label excerpts.
Valsartan blocks the effects of angiotensin II.
Not supported by the supplied label excerpts.
Angiotensin II constricts blood vessels and increases blood pressure.
Not supported by the supplied label excerpts.
Together, these actions help to reduce the workload on the heart and improve its function.
Not supported by the supplied label excerpts.
The active ingredients in Entresto are sacubitril and valsartan.
Not supported by the supplied label excerpts.
Entresto contains valsartan, which is an ARB, and includes sacubitril, a neprilysin inhibitor.
Not supported by the supplied label excerpts.
Standard ARBs only block the angiotensin II receptor.
Not supported by the supplied label excerpts.
Entresto includes sacubitril in addition to blocking the harmful effects of angiotensin II to increase natriuretic peptides.
Not supported by the supplied label excerpts.
Common side effects of Entresto include hypotension (low blood pressure).
Not supported by the supplied label excerpts.
Common side effects of Entresto include hyperkalemia (high potassium levels).
Not supported by the supplied label excerpts.
Common side effects of Entresto include cough.
Not supported by the supplied label excerpts.
Common side effects of Entresto include dizziness.
Not supported by the supplied label excerpts.
Common side effects of Entresto include elevated serum creatinine.
Not supported by the supplied label excerpts.
The primary clinical trial supporting Entresto's use is the PARADIGM-HF study.
Not supported by the supplied label excerpts.
In the PARADIGM-HF study, Entresto significantly reduced the risk of cardiovascular death or heart failure hospitalization compared to an ACE inhibitor (enalapril) in patients with heart failure with reduced ejection fraction.
Not supported by the supplied label excerpts.
Entresto is manufactured by Novartis.
Not supported by the supplied label excerpts.
The recommended starting dose for Entresto is typically 50 mg or 100 mg twice daily.
Not supported by the supplied label excerpts.
The dose is titrated upwards to a target dose of 200 mg twice daily, as tolerated.
Not supported by the supplied label excerpts.
Key risks associated with Entresto include angioedema.
Not supported by the supplied label excerpts.
Angioedema associated with Entresto can cause swelling of the face, lips, tongue, or throat.
Not supported by the supplied label excerpts.
Angioedema can be life-threatening.
Not supported by the supplied label excerpts.
Entresto has shown superiority to ACE inhibitors in reducing cardiovascular mortality and heart failure hospitalizations in the PARADIGM-HF trial.
Not supported by the supplied label excerpts.
Entresto is considered a cornerstone therapy for patients with heart failure with reduced ejection fraction.
Not supported by the supplied label excerpts.
If a dose of Entresto is missed, it should be taken as soon as remembered.
Not supported by the supplied label excerpts.
If a missed Entresto dose is almost time for the next scheduled dose, the missed dose should be skipped.
Not supported by the supplied label excerpts.
Two doses of Entresto should not be taken at the same time.
Not supported by the supplied label excerpts.
Entresto is contraindicated in patients with a known history of angioedema related to previous treatment with an ARB or ARNI.
Not supported by the supplied label excerpts.
Entresto is contraindicated in patients with concomitant use of neprilysin inhibitors.
Not supported by the supplied label excerpts.
Entresto is contraindicated in patients with hypersensitivity to sacubitril or valsartan.
Not supported by the supplied label excerpts.
Entresto can cause fetal toxicity including injury and death to a developing fetus.
Overlapping partial support exists, but wording includes 'injury'—the provided excerpts specifically discuss fetal harm and fetal/neonatal morbidity/mortality and consequences (e.g., anuria, renal failure, lung hypoplasia, skeletal deformations, hypotension, death). 'Injury' is not a precise phrasing from the excerpt; the core concept is supported though.
Entresto can cause fetal toxicity including injury and death to a developing fetus.
If treated as broader than the excerpt, 'injury' is not explicitly enumerated as such in the provided text (though multiple specific injuries/conditions are described).
Contradictions
Important Omissions
For pregnancy management: the label excerpt specifies that 'Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death' and describes fetal/neonatal adverse reactions (e.g., oligohydramnios leading to anuria/renal failure, lung hypoplasia, skeletal deformations, hypotension, death). The AI output does not include these specific trimester-dependent and mechanistic details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The pregnancy/fetal toxicity concept is supported by the provided label excerpts, but the AI output does not reflect key trimester-dependent and clinical consequence details from the label text, and many other drug-related safety elements were not verifiable from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Only pregnancy/fetal toxicity content can be confirmed from the supplied label excerpts; most other claims (indication, dosing, contraindications, side effects, trials, and missed-dose instructions) are unsupported because corresponding label text was not provided.
Suggested Improvement
Limit evaluation and statements to the provided label sections (5.1 and 8.1) or supply additional FDA label sections needed for verification of indication, dosage/administration, contraindications, warnings, adverse reactions, and dosing guidance.